The limits and challenges of antiobesity pharmacotherapy

Gadde, Kishore M.; Atkins, Katelyn D

doi:10.1080/14656566.2020.1748599

Cited by 35 publications

(29 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…19,20 Commonly reported adverse effects of topiramate include paresthesia, dizziness, psychomotor slowing, nausea, visual disturbances, and dysgeusia. 11,[21][22][23] Three placebo-controlled trials (CONQUER, EQUIP, and SEQUEL) studied the short and long-term effects of phentermine-topiramate. 21,22,24 A substantial proportion of subjects discontinued use of phentermine-topiramate due to adverse effects, which most commonly included dry mouth, paresthesia, and constipation.…”

Section: Topiramate and Phentermine-topiramatementioning

confidence: 99%

“…Several compounds related to amphetamine are marketed for short-term (ie, ≤12 weeks) use in obesity, and include phentermine, diethylpropion, phendimetrazine, and benzphetamine. 11,12 These sympathomimetic amines work primarily as anorectic agents through variable effects on norepinephrine release or reuptake at synaptic terminals, and may increase resting energy expenditure. 13,14 Only phentermine was considered for the purposes of this review as this drug accounts for the overwhelming majority of prescriptions in the United States.…”

Section: Phenterminementioning

confidence: 99%

“…Furthermore, despite the high prevalence of GERD in this population, there has been little published on the effects of anti-obesity medications on GERD symptoms. 10,11 The focus of this review is to consider the current pharmacotherapeutic options for the treatment of obesity and their potential influence on symptoms of GERD.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Medical Management of Obesity as it Affects Reflux

Haddad

Shah

2021

Foregut: The Journal of the American Foregut Society

View full text Add to dashboard Cite

Gastroesophageal reflux disease (GERD) is common among the American population and increasing in prevalence, with obesity being implicated as one of the strongest risk factors for its development. Little is known about the effects of currently prescribed anti-obesity medications on GERD symptoms. This review aims to explore the current literature on FDA-approved and off-label anti-obesity pharmacotherapy with respect to their influence on GERD and interactions with commonly prescribed GERD medications.

show abstract

Section: Topiramate and Phentermine-topiramatementioning

confidence: 99%

Section: Phenterminementioning

confidence: 99%

See 1 more Smart Citation

Medical Management of Obesity as it Affects Reflux

Haddad

Shah

2021

Foregut: The Journal of the American Foregut Society

View full text Add to dashboard Cite

show abstract

“…Obesity, as a chronic recurrent disease, is known to increase the risk of developing T2MD, hypertension, dyslipidemias, CVDs, NAFLD, and other diseases, leading to a poor quality of life and increased mortality ( 167 ). Obesity is considered to be related to increased appetite, changes in the levels of gastrointestinal hormones, increased fat mass, and disorders of satiety and satiation mechanisms ( 168 ).…”

Section: Effects On Obesitymentioning

confidence: 99%

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

et al. 2021

View full text Add to dashboard Cite

Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their attributes such as body weight loss, protection of islet β cells, promotion of islet β cell proliferation and minimal side effects. Studies have found that GLP-1R is widely distributed on pancreatic and other tissues and has multiple biological effects, such as reducing neuroinflammation, promoting nerve growth, improving heart function, suppressing appetite, delaying gastric emptying, regulating blood lipid metabolism and reducing fat deposition. Moreover, GLP-1RAs have neuroprotective, anti-infectious, cardiovascular protective, and metabolic regulatory effects, exhibiting good application prospects. Growing attention has been paid to the relationship between GLP-1RAs and tumorigenesis, development and prognosis in patient with T2DM. Here, we reviewed the therapeutic effects and possible mechanisms of action of GLP-1RAs in the nervous, cardiovascular, and endocrine systems and their correlation with metabolism, tumours and other diseases.

show abstract

“…This is due to difficult long-term adherence, safety concerns, and disappointing results for sustaining weight after drug discontinuation [24]. In addition, no anti-obesity drugs have demonstrated a reduction in major adverse cardiovascular events or outcomes [25]. BP: blood pressure; LDL: low-density lipoprotein.…”

Section: Chrono-nutritional Interventions and Their Noveltymentioning

confidence: 99%

Chrononutrition in Cardiometabolic Health

Katsi

Papakonstantinou

Σουλαϊδόπουλος

et al. 2022

JCM

View full text Add to dashboard Cite

In recent years, a healthy balanced diet together with weight reduction has risen to the forefront of minimizing the impact of cardiovascular disease. There is evidence that metabolic processes present circadian rhythmicity. Moreover, the timing of food consumption exerts a powerful influence on circadian rhythms. In this context, the subject of chrononutrition, described as the alignment of timing of food intake to the rhythms imposed by the circadian clock, has attracted considerable interest for possible beneficial effects on cardiovascular health. Current human studies suggest that chrononutrition-based dietary interventions could reduce the risk for cardiovascular disease by improving weight control, hypertension, dyslipidemia, and diabetes. However, meta-analysis of randomized control trials in this topic present varying and somehow conflicting results. Even the traditional association of breakfast skipping with adverse cardiovascular outcomes is nowadays controversial. Therefore, long-term and fairly consistent studies on the effect of chrononutrition on cardiovascular outcomes are needed. The purpose of this review is to provide concise evidence of the most recent literature involving the effects of chrononutrition and the specific chrononutrition-based dietary interventions, in particular time-restricted eating, on body weight and other cardiovascular disease risk factors.

show abstract

The limits and challenges of antiobesity pharmacotherapy

Cited by 35 publications

References 82 publications

Medical Management of Obesity as it Affects Reflux

Medical Management of Obesity as it Affects Reflux

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

Chrononutrition in Cardiometabolic Health

Contact Info

Product

Resources

About